Literature DB >> 3022182

The effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal and limbic catecholamine neurones in white and black mice. Antagonism by monoamine oxidase inhibitors.

A J Bradbury, B Costall, P G Jenner, M E Kelly, C D Marsden, R J Naylor.   

Abstract

Albino mice and pigmented mice were treated for 6 days with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at the maximum tolerated doses (2 days at 30 mg/kg i.p., 2 days at 40 mg/kg i.p. and 2 days at 50 mg/kg i.p. in white mice, 6 days at 30 mg/kg i.p. in pigmented mice) and the effects of simultaneous treatment with the monoamine oxidase inhibitors, deprenyl (1 mg/kg, i.p.), MDL 72145 (0.5 mg/kg, i.p.) and clorgyline (5 mg/kg, i.p.), determined behaviourally (daily for 6 days and for 4 days after withdrawal) and biochemically (92 hr after withdrawal of drug). In albino mice MPTP caused depletions of dopamine (90%), dihydroxyphenylacetic acid (DOPAC; 82%) and homovanillic acid (HVA; 65%) in the striatum and in dopamine (54%), DOPAC (51%) and HVA (53%) in the nigra. However, MPTP was not selective in its action since the levels of dopamine and its metabolites were also reduced in limbic tissue. Further, MPTP affected the function of noradrenaline, with reduced levels in tissues of the striatum (74%) and nigra (46%). Pigmented mice were as susceptible as albino mice to the actions of MPTP to reduce the levels of dopamine and metabolites in the striatum. However, the limbic areas and substantia nigra of the pigmented mouse were more resistant to the actions of MPTP. Treatment with deprenyl and MDL 72145 (but not clorgyline) could be shown to reduce the biochemical and behavioural consequences of the action of MPTP (although behavioural changes, development of severe motor incapacitation and prostrate appearance, appeared to be non-specific).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3022182     DOI: 10.1016/0028-3908(86)90016-x

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease.

Authors:  R K Schwarting; M Sedelis; K Hofele; G W Auburger; J P Huston
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

Review 2.  Genetic factors in neurotoxicology and neuropharmacology: a critical evaluation of the use of genetics as a research tool.

Authors:  M F Festing
Journal:  Experientia       Date:  1991-10-15

3.  Different effects of 1-methyl-4-phenyl-pyridinium (MPP+) on monoamine oxidase of dopaminergic terminals in caudate nucleus slices from pigmented and from albino rabbits.

Authors:  A Lupp; C H Lücking; L Hedler; T J Feuerstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

4.  The effects of piroxicam in the attenuation of MPP+/MPTP toxicity in vitro and in vivo.

Authors:  Y Soliman; T Jackson; E Mazzio; K F A Soliman
Journal:  Neurochem Res       Date:  2008-07-09       Impact factor: 3.996

Review 5.  MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease.

Authors:  I J Kopin
Journal:  Environ Health Perspect       Date:  1987-11       Impact factor: 9.031

6.  Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease.

Authors:  Xiao Hong Wang; Gang Lu; Xiang Hu; Kam Sze Tsang; Wing Hang Kwong; Feng Xia Wu; Hai Wei Meng; Shu Jiang; Shu Wei Liu; Ho Keung Ng; Wai Sang Poon
Journal:  BMC Neurosci       Date:  2012-11-14       Impact factor: 3.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.